We published safety, biomarker, and clinical outcome data in @NatureMedicine from the Phase 1b study of our investigational CD73 inhibitor.
This research underscores a potential novel approach to treating metastatic #PancreaticCancer for which new treatment options are critically needed. Explore the research: bit.ly/3PJjSdl
+++
“Investigating new approaches like CD73 inhibition with a small molecule is a critical step in exploring how targeting adenosine, a key driver of immune suppression, might ultimately make a meaningful impact on patient care. For people with pancreatic cancer, the unmet need for new treatment options is profound. These findings support CD73 as a therapeutic target in pancreatic cancer and we look forward to seeing the results of the Phase 3 PRISM-1 study in early 2027.”
Zev A. Wainberg, M.D., MSc
Co-Director of the GI Oncology Program at University of California Los Angeles and a principal investigator of the ARC-8 trial.
English
